摘要
目的建立反相高效液相色谱法测定精神分裂症患者富马酸喹硫平血药浓度的方法学,探讨其血药浓度与患者年龄、性别、服药剂量及临床效应的关系。方法采用高效液相色谱法测定76例单一服用富马酸喹硫平精神分裂症住院患者治疗前及治疗后第2,4,6周血药浓度,并进行BPRS量表评定及相关性分析。结果富马酸喹硫平血药浓度在50～500ng·mL-1内有良好线性关系(r=09850)。日剂量在50～450mg内血药浓度随剂量的增大而升高,但与服药患者年龄、性别无显著相关性。血药浓度在126～350ng·mL-1范围内临床效果较好。结论测定方法简便、准确、专一性强,可用于富马酸喹硫平血药浓度监测。富马酸喹硫平治疗窗浓度为126～350ng·mL-1。
OBJECTIVE: To establish a RP-HPLC method for the determination of quetiapine fumarate concentration in patients with schizophrenia, and to study the relationship between serum concentration and clinical response. METHODS: A HPLC method was used to determine quetiapine fumarate concentration. Blood samples were collected in 76 schizophrenia inpatients before or at the end of 2, 4, 6 weeks of quetiapine fumarate treatment and the therapeutic efficacy was measured by BPRS. RESULTS: The standard curve was linear over the range of 50 ∼ 500 ng.mL-1 of quetiapine fumarate in serum (r = 0.985 0). The serum concentrations were proportionally increased with daily dose in the range of 50 ∼ 450 mg, but no significant correlation between dose and age/sex was discovered. The optimal therapeutic concentration was estimated from 126 to 350 ng.mL-1. CONCLUSION: The assay was simple, precise and usable for therapeutic quetiapine fumarate monitoring. The optimal concentration window was suggetted as 126 ∼ 350 ng.mL-1.
出处
《中国药学杂志》
EI
CAS
CSCD
北大核心
2004年第12期928-930,共3页
Chinese Pharmaceutical Journal
